Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Net Cash Flow of -$89.6 million for Q1 2026, down 628.86% year-over-year from $17.0 million in Q1 2025, and down 188.8% quarter-over-quarter from $101.0 million in Q4 2025.
Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Net Cash Flow for 7 consecutive years, with -$89.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 628.86% year-over-year to -$89.6 million; the TTM figure through Mar 2026 stood at -$23.9 million (down 133.58% YoY), while the FY2025 annual figure was $82.7 million, up 74.81% from the prior year.
- Net Cash Flow fell to -$89.6 million in Q1 2026 per IKT's latest filing, from $101.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $101.0 million in Q4 2025 and bottomed at -$89.6 million in Q1 2026.
- Historically, Net Cash Flow has averaged $519022.2 across 5 years, with a median of -$2.2 million in 2024.
- Annual changes were most pronounced in 2024 — Net Cash Flow surged 1075.7% — and 2025, when it slumped 1716.49%.
- Inhibikase Therapeutics' Net Cash Flow stood at $1.4 million in 2022, then slumped by 504.95% to -$5.7 million in 2023, then soared by 1075.7% to $55.6 million in 2024, then jumped by 81.64% to $101.0 million in 2025, then plunged by 188.8% to -$89.6 million in 2026.
- Business Quant data shows IKT's Net Cash Flow at -$89.6 million in Q1 2026, $101.0 million in Q4 2025, and -$39.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -18.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.37 Mn |
| Jun 30, 2026 | -18.37 Mn |
| Mar 31, 2026 | -89.65 Mn |
| Mar 31, 2026 | -89.65 Mn |
| Dec 31, 2025 | 100.95 Mn |
| Dec 31, 2025 | 100.95 Mn |
| Sep 30, 2025 | -39.47 Mn |
| Sep 30, 2025 | -39.47 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Mar 31, 2025 | 16.95 Mn |
| Mar 31, 2025 | 16.95 Mn |
| Dec 31, 2024 | 55.58 Mn |
| Dec 31, 2024 | 55.58 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Jun 30, 2024 | 733,109.00 |
| Jun 30, 2024 | 733,109.00 |
| Mar 31, 2024 | -6.81 Mn |
| Mar 31, 2024 | -6.81 Mn |